Overexpression of IGF2 is seen in at least 95% of ACC tumor samples studied [10], prompting clinical trials employing Insulin-Like Growth Factor 1 Receptor (IGF1R) inhibitors [11]. This evidence concerns the gene IGF1R and neoplasm.